PMCB - PharmaCyte Biotech, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PMCB

PHARMACYTE BIOTECH, INC.

NASDAQ

$0.53

▲ UP 3.64% (0.02)

KEY STATISTICS

Market Cap$5.72 M

52w High$1.51

52w Low$0.50

Dividend Yield—

Frequency—

P/E0.37

Volume92.79K

Shares Out.10.74M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joshua N. Silverman

COMPENSATION 2026

Salary$375,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$45,257

Total$520,257

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 2, 2013

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateAug 24, 2026

DayMonday

Rev. Est.—

AUG

MON

SPLIT RECORD

DATE	TYPE	RATIO
2021-07-12	Reverse	1:1550
2003-12-08	Forward	3:1

PRICE

$0.53 ▲ UP 3.64% (+$0.02)

OVERLAYS

About PharmaCyte Biotech, Inc.

https://pharmacyte.com ↗

PharmaCyte Biotech develops cellular therapies using Cell-in-a-Box technology for cancer, diabetes, and malignant ascites, including treatments for pancreatic cancer, insulin-dependent diabetes, and cannabis-based cancer therapies.

INDUSTRY

Biotechnology

A PRODUCT PHARMACYTE BIOTECH, INC. IS KNOWN FOR

CypCaps

CypCaps, PharmaCyte's lead product for pancreatic cancer, uses encapsulated genetically engineered cells to locally activate chemotherapy, enhancing efficacy and reducing side effects.